Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Distant, D. A.
Right arrow Articles by Gonwa, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Distant, D. A.
Right arrow Articles by Gonwa, T. A.

Journal of the American Society of Nephrology, Vol 4, 129-136, Copyright © 1993 by American Society of Nephrology

REVIEWS

The kidney in liver transplantation

DA Distant and TA Gonwa
Transplantation Services, Baylor University Medical Center, Dallas, TX 75246.

Renal dysfunction often complicates the course of liver transplant recipients. Preoperative renal dysfunction, including hepatorenal syndrome (HRS) may be present. Assessment of renal function in the pretransplant patient with end-stage liver disease is fraught with pitfalls. Direct measurement of GFR by a method other than creatinine clearance is recommended wherever possible. Preoperative renal biopsy should also be considered in those patients with renal dysfunction in whom the diagnosis of HRS is not definite. With the routine use of veno venous bypass, renal perfusion is maintained and intraoperative events generally do not play a significant role in the development of postoperative dysfunction. Postoperatively immunosuppressive medications such as CsA or FK506 account for most of the renal dysfunction that is observed. Other factors such as graft dysfunction, sepsis, and nephrotoxic drugs may also participate in renal impairment. The exact mechanism of cyclosporine or FK506 nephrotoxicity remains unknown. In liver transplant recipients, no convincing therapeutic strategies exist to combat nephrotoxicity other than dose reduction of immunosuppressive therapy. Patients with HRS can be successfully treated by liver transplantation with recovery of renal function and with patient survival rates comparable to recipients without HRS, despite increased morbidity.


This article has been cited by other articles:


Home page
 Arch SurgHome page
E. Moreno-Gonzalez, J. C. Meneu-Diaz, I. Garcia, F. Perez Cerda, M. Abradelo, C. Jimenez, C. Loinaz, R. Gomez, A. Gimeno, and A. Moreno
Simultaneous Liver-Kidney Transplantation for Adult Recipients With Irreversible End-Stage Renal Disease
Arch Surg, November 1, 2004; 139(11): 1189 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. L. Conesa, F. Valero, J. C. Nadal, F. J. Fenoy, B. Lopez, B. Arregui, and M. G. Salom
N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R730 - R737.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. H. WILKINSON and D. J. COHEN
Renal Failure in the Recipients of Nonrenal Solid Organ Transplants
J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1136 - 1144.
[Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673